Impact of bisoprolol transdermal patch on early recurrence during the blanking period after atrial fibrillation ablation
Abstract Background Early recurrences of atrial arrhythmias (ERAAs) after ablation may require therapeutic intervention. The optimal medical therapy that prevents ERAAs requires clarification. This study aimed to compare the incidence of ERAAs between patients who received or did not receive bisopro...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-06-01
|
| Series: | Journal of Arrhythmia |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/joa3.12538 |
| _version_ | 1818662142336827392 |
|---|---|
| author | Yuya Suzuki Masaru Kuroda Tomoo Fujioka Masayuki Kintsu Tsubasa Noda Akinori Matsumoto Masahito Kawata |
| author_facet | Yuya Suzuki Masaru Kuroda Tomoo Fujioka Masayuki Kintsu Tsubasa Noda Akinori Matsumoto Masahito Kawata |
| author_sort | Yuya Suzuki |
| collection | DOAJ |
| description | Abstract Background Early recurrences of atrial arrhythmias (ERAAs) after ablation may require therapeutic intervention. The optimal medical therapy that prevents ERAAs requires clarification. This study aimed to compare the incidence of ERAAs between patients who received or did not receive bisoprolol transdermal patches (BTPs) at 3 months postablation. Methods This single‐center retrospective study enrolled 203 consecutive patients with paroxysmal atrial fibrillation (AF) who had undergone their first ablation, comprising 59 in the BTP group and 144 in the non‐BTP group. Follow‐up assessments were conducted monthly for 3 months. We evaluated the incidence of ERAAs. Results During the initial 1‐week observational period, the rate of ERAAs was lower in the BTP group (5.0%) than that in the non‐BTP group (18.8%) (P = .013). At 3 months postablation, the rate of ERAAs was lower in the BTP group (6.8%) than that in the non‐BTP group (25.7%) (P = .002). The cumulative freedom from ERAAs was significantly lower in the BTP group than in the non‐BTP group (log‐rank: P = .003). Administering BTPs was an independent factor that protected against ERAAs (odds ratio 0.181, [95% confidence interval 0.059‐0.559], P = .003). Conclusion BTPs may prevent ERAAs after ablation. |
| first_indexed | 2024-12-17T04:56:15Z |
| format | Article |
| id | doaj.art-5528aaa7622d4024a20b9fecf6b0b817 |
| institution | Directory Open Access Journal |
| issn | 1880-4276 1883-2148 |
| language | English |
| last_indexed | 2024-12-17T04:56:15Z |
| publishDate | 2021-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Arrhythmia |
| spelling | doaj.art-5528aaa7622d4024a20b9fecf6b0b8172022-12-21T22:02:41ZengWileyJournal of Arrhythmia1880-42761883-21482021-06-0137360761510.1002/joa3.12538Impact of bisoprolol transdermal patch on early recurrence during the blanking period after atrial fibrillation ablationYuya Suzuki0Masaru Kuroda1Tomoo Fujioka2Masayuki Kintsu3Tsubasa Noda4Akinori Matsumoto5Masahito Kawata6Department of Cardiovascular Medicine Akashi Medical Center Akashi Hyogo JapanDepartment of Cardiovascular Medicine Akashi Medical Center Akashi Hyogo JapanDepartment of Cardiovascular Medicine Akashi Medical Center Akashi Hyogo JapanDepartment of Cardiovascular Medicine Akashi Medical Center Akashi Hyogo JapanDepartment of Cardiovascular Medicine Akashi Medical Center Akashi Hyogo JapanDepartment of Cardiovascular Medicine Akashi Medical Center Akashi Hyogo JapanDepartment of Cardiovascular Medicine Akashi Medical Center Akashi Hyogo JapanAbstract Background Early recurrences of atrial arrhythmias (ERAAs) after ablation may require therapeutic intervention. The optimal medical therapy that prevents ERAAs requires clarification. This study aimed to compare the incidence of ERAAs between patients who received or did not receive bisoprolol transdermal patches (BTPs) at 3 months postablation. Methods This single‐center retrospective study enrolled 203 consecutive patients with paroxysmal atrial fibrillation (AF) who had undergone their first ablation, comprising 59 in the BTP group and 144 in the non‐BTP group. Follow‐up assessments were conducted monthly for 3 months. We evaluated the incidence of ERAAs. Results During the initial 1‐week observational period, the rate of ERAAs was lower in the BTP group (5.0%) than that in the non‐BTP group (18.8%) (P = .013). At 3 months postablation, the rate of ERAAs was lower in the BTP group (6.8%) than that in the non‐BTP group (25.7%) (P = .002). The cumulative freedom from ERAAs was significantly lower in the BTP group than in the non‐BTP group (log‐rank: P = .003). Administering BTPs was an independent factor that protected against ERAAs (odds ratio 0.181, [95% confidence interval 0.059‐0.559], P = .003). Conclusion BTPs may prevent ERAAs after ablation.https://doi.org/10.1002/joa3.12538ablationatrial fibrillationbisoprolol transdermal patchearly recurrencesβ‐blocker |
| spellingShingle | Yuya Suzuki Masaru Kuroda Tomoo Fujioka Masayuki Kintsu Tsubasa Noda Akinori Matsumoto Masahito Kawata Impact of bisoprolol transdermal patch on early recurrence during the blanking period after atrial fibrillation ablation Journal of Arrhythmia ablation atrial fibrillation bisoprolol transdermal patch early recurrences β‐blocker |
| title | Impact of bisoprolol transdermal patch on early recurrence during the blanking period after atrial fibrillation ablation |
| title_full | Impact of bisoprolol transdermal patch on early recurrence during the blanking period after atrial fibrillation ablation |
| title_fullStr | Impact of bisoprolol transdermal patch on early recurrence during the blanking period after atrial fibrillation ablation |
| title_full_unstemmed | Impact of bisoprolol transdermal patch on early recurrence during the blanking period after atrial fibrillation ablation |
| title_short | Impact of bisoprolol transdermal patch on early recurrence during the blanking period after atrial fibrillation ablation |
| title_sort | impact of bisoprolol transdermal patch on early recurrence during the blanking period after atrial fibrillation ablation |
| topic | ablation atrial fibrillation bisoprolol transdermal patch early recurrences β‐blocker |
| url | https://doi.org/10.1002/joa3.12538 |
| work_keys_str_mv | AT yuyasuzuki impactofbisoprololtransdermalpatchonearlyrecurrenceduringtheblankingperiodafteratrialfibrillationablation AT masarukuroda impactofbisoprololtransdermalpatchonearlyrecurrenceduringtheblankingperiodafteratrialfibrillationablation AT tomoofujioka impactofbisoprololtransdermalpatchonearlyrecurrenceduringtheblankingperiodafteratrialfibrillationablation AT masayukikintsu impactofbisoprololtransdermalpatchonearlyrecurrenceduringtheblankingperiodafteratrialfibrillationablation AT tsubasanoda impactofbisoprololtransdermalpatchonearlyrecurrenceduringtheblankingperiodafteratrialfibrillationablation AT akinorimatsumoto impactofbisoprololtransdermalpatchonearlyrecurrenceduringtheblankingperiodafteratrialfibrillationablation AT masahitokawata impactofbisoprololtransdermalpatchonearlyrecurrenceduringtheblankingperiodafteratrialfibrillationablation |